Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

FRIENDSWOOD, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new systematic review and meta-analysis (SRMA) demonstrating that the TissueCypher® Barrett's Esophagus test provides clinically validated risk stratification for patients with Barrett's esophagus (BE). The findings confirm that TissueCypher can outperform traditional pathology or clinical factors alone to identify patients at increased risk of developing esophageal cancer.

GlobeNewsWire • Dec 12, 2025

Are Medical Stocks Lagging Cronos Group (CRON) This Year?

Here is how Cronos Group (CRON) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.

Zacks Investment Research • Dec 11, 2025

Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

FRIENDSWOOD, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of an independent expert consensus paper titled “31-Gene Expression Profiling for Cutaneous Melanoma: An Expert Consensus Panel,” which endorses the Company's DecisionDx-Melanoma test. The paper can be viewed here.1 “This consensus translates the robust data supporting DecisionDx-Melanoma into practical direction for clinicians,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.

GlobeNewsWire • Dec 9, 2025

Here's Why 'Trend' Investors Would Love Betting on Castle Biosciences (CSTL)

Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Investment Research • Dec 8, 2025

Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable

Castle Biosciences (CSTL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Investment Research • Nov 21, 2025

5 Stocks With Recent Price Strength Amid Wall Street Volatility

CSTL, IDN, PANL, FSRL and PRM are showing sharp price strength amid renewed Wall Street volatility.

Zacks Investment Research • Nov 20, 2025

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

FRIENDSWOOD, Texas, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized by the Houston Chronicle as a Houston Top Workplace, which celebrates people-focused, standout workplace cultures. This marks the fifth consecutive year the Company has been ranked among the Houston metro area's esteemed workplaces.

GlobeNewsWire • Nov 17, 2025

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

Castle will present new data showing the clinical value of DecisionDx-Melanoma in improving sentinel lymph node biopsy decision making at Dermato-Onco2025.

GlobeNewsWire • Nov 14, 2025

Forget the Fed, Bet on These 4 Stocks With Increasing Cash Flows

Four rising cash-flow stocks, including PRM, TILE, CSTL and GLDD, stand out with upgraded earnings estimates and strong VGM scores.

Zacks Investment Research • Nov 14, 2025

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

Castle Biosciences' executive management will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on 12/2/25 at 1:10pm ET

GlobeNewsWire • Nov 11, 2025